Prediction of the Risk of Conversion from Mild Cognitive Impairment to Alzheimer`S Disease Dementia
Gisele Santos Gonçalves, Lucas Ferreira Alves, Maria Aparecida Camargos Bicalho, Caio Coelho Moreira, Edna Afonso Reis, Ieda de Fátima Oliveira Silva, Maria das Graças Carvalho
Journal of Advances in Medicine and Medical Research · pp. 147–160 · Published 25 Jul 2025
10.9734/jammr/2025/v37i75890Abstract
Purpose: Identification of individuals at high risk of progressive cognitive deterioration may be useful for prognosis and intervention. The present investigation addressed the development of an algorithm for predicting the risk of conversion from mild cognitive impairment (MCI) to Alzheimer’s disease (AD) based on clinical, sociodemographic and laboratory data over a three-year clinical follow-up. Methods: Thirty-eight elderly patients of both sexes, diagnosed with MCI, participated in the present study. A total of 72 variables including inflammatory, hemostatic and vascular parameters, in addition to clinical, sociodemographic and cognitive evolution data of the patients were used in the construction of an algorithm to estimate the probability of an individual evolving from MCI to AD within a three-year period. Results: Age, gender, peak of thrombin generation test in the presence of activated protein C (TG peak+aPC) and homocysteine were the variables found independently associated with the highest risk of conversion from MCI to AD, that is, male patients aged ≥ 80 years old, TG peak+aPC ≥58nM and homocysteine levels ≥ 30 µmol/L. Conclusion: Based on the results presented here, we propose that elderly patients, mainly males, should have their serum homocysteine levels and hemostatic status constantly monitored and, in cases of hyperhomocysteinemia and hypercoagulability, control measures should be taken immediately, provided that these changes are potentially modifiable. We suggest that the adoption of measures to control these undesirable conditions may reduce the chances of patients evolving from MCI to AD.
Cited by 0
No indexed citations yet.
Related research
- Proposal and Point of View on Targeting α-synuclein for the Treatment of Parkinson's Disease — shares topic coverage
- Efficacy and Tolerability of MlC601 in Patients with Mild to Moderate Alzheimer Disease who were Unable to Tolerate or Failed to Benefit from Treatment with Rivastigmine — shares topic coverage
- Alzheimer Disease and Environmental Exposure to Neurotoxic Factors: A Controversy — shares topic coverage
- Protective Role of Foeniculum vulgare Mill. in Brain Disorders; A New Window — shares topic coverage
- Magnesium and Memory: Unraveling the Physiological Tapestry of Alzheimer's Disease — shares topic coverage
Article metrics
Real usage data collected on this platform.
7
Page views
0
PDF downloads
0
Outbound clicks
0
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.